[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sstr-expressing-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sstr-expressing-tumors":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100638922","a-comparison-of-68gadotatate-and-18fambf3tate-for-the-staging-and-assessment-of-neuroendocrine-malignancies-100638922",false,"NCT07621146","A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies","A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study","NET-COMPARE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients referred for and meeting institutional criteria for a \\[68Ga\\]DOTATATE PET\u002FCT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).\n\nExclusion Criteria:\n\n* Pregnant and breast-feeding patients.\n* Patients unwilling or unable to undergo a second PET\u002FCT.\n* Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET\u002FCT bore (70cm diameter).","ALL","18 Years",{"count":20,"type":21},51,"ESTIMATED","OBSERVATIONAL","Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.",[25,26,27,28],"Neuroendocrine Tumors, NET","Pheochromocytoma\u002FParaganglioma","SSTR-expressing Tumors","Medullary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-27",{"date":32,"type":33},"2026-06-02","ACTUAL",{"date":35,"type":21},"2026-09-15",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"British Columbia Cancer Agency","OTHER"]